| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 03/01/2005 | US6861414 Methods for enhancing graft survival by modulating heme oxygenase activity |
| 03/01/2005 | US6861408 Therapeutic anti-melanoma compounds |
| 03/01/2005 | US6861399 Cleaning compositions containing human serine protease T |
| 03/01/2005 | US6861256 Therapeutic and diagnostic tools for impaired glucose tolerance conditions |
| 03/01/2005 | US6861057 Immunogenic β-amyloid peptide |
| 03/01/2005 | CA2390110C Modular transport systems for molecular substances and production and use thereof |
| 02/24/2005 | WO2005017170A2 Methods of unidirectional, site-specific integration into a genome, compositions and kits for practicing the same |
| 02/24/2005 | WO2005017165A1 Stem cell beacon |
| 02/24/2005 | WO2005017164A1 Vigilant cells |
| 02/24/2005 | WO2005017153A2 Methods for synthesis of defined polynucleotides |
| 02/24/2005 | WO2005017151A1 End-deficient mutant of ip3 receptor protein inducing apoptosis |
| 02/24/2005 | WO2005017101A2 Avian adenoassociated virus (aaav) and uses thereof |
| 02/24/2005 | WO2005016964A2 Canine specific growth hormone releasing hormone |
| 02/24/2005 | WO2005016960A2 Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
| 02/24/2005 | WO2005016414A2 Use of receptor sequences for immobilizing gene vectors on surfaces |
| 02/24/2005 | WO2005016367A1 Therapeutic preparation for hematopoietic disease |
| 02/24/2005 | WO2005016355A1 Intravascular delivery of non-viral nucleic acid |
| 02/24/2005 | WO2005016274A2 Rnai treatment of eye disease |
| 02/24/2005 | WO2004099377A3 An autologous upregulation mechanism allowing optimized cell type-specific and regulated gene expression cells |
| 02/24/2005 | WO2004090145A3 Compounds and methods to enhance raav transduction |
| 02/24/2005 | WO2004076627A3 Method of using adenoviral vectors with increased persistence in vivo |
| 02/24/2005 | WO2004055196A3 Method for identifying risk of breast cancer and treatments thereof |
| 02/24/2005 | WO2004015062A3 Methods and compositions relating to gene silencing |
| 02/24/2005 | WO2003102206A3 Sgk and nedd used as diagnostic and therapeutic targets |
| 02/24/2005 | WO2003061582A3 Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach |
| 02/24/2005 | US20050044588 Methods and substances for preventing and treating autoimmune disease |
| 02/24/2005 | US20050043788 Drug-eluting stent |
| 02/24/2005 | US20050043511 G-protein coupled receptor lustr2 and uses thereof |
| 02/24/2005 | US20050043262 Administering antisense oligonucleotide molecule directed to the nucleotide sequence of p21Waf1/Cip1; treating diseases associated with abnormal cell growth and proliferation |
| 02/24/2005 | US20050043261 RNA of ribonucleoprotein U1 snRNP with a modification at the 5' end of its nucleotide sequence, is hybridized in at least one region of the 3' terminal exon of a target mRNA of the gene to be inactivated. |
| 02/24/2005 | US20050043260 cardiomyocyte differentiation from a non-cardiomyocyte cell; cardiac specific polynucleotide selected from Nkx2.5, GATA4, MEF2C, Tbx5, CRIPTO, NODAL, and cardiac myosin heavy chain |
| 02/24/2005 | US20050043259 Using transfer rna splicing endonuclease and oligonucleotide probes to preferentially locate, hybridize and split target messenger rna sequences comprising bulge-helix-bulge conformations |
| 02/24/2005 | US20050043258 Contacting a salivary gland cell of a mammal with a protein selected from IFN-alpha, IL-10, sTNFR, TGF- beta , IL-4 and VIP, anti-TNF antibody, IL1-RA, other antibodies to proinflammatory cytokines, soluble gp39, soluble CD40, aquaporin-1 and aquaporin |
| 02/24/2005 | US20050043243 Polypeptide for use in treatment of energy balance defects, energy balance involving energy metabolism, nutritional state, lipid storage and the like, food intake and metabolism of carbohydrates and lipids to generate energy |
| 02/24/2005 | US20050043241 Use of inhibitors of given amino acid sequence; inhibit phosphorylation of a transcription factor; can be used to treat or prevent diabetes, ionizing radiation damage, autoimmune diseases, ischemia/reperfusion injuries, heart hypertrophies, cancer |
| 02/24/2005 | US20050043237 Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use |
| 02/24/2005 | US20050043235 Use of VEGF-C or VEGF-D in reconstructive surgery |
| 02/24/2005 | US20050043219 Derivatized oligonucleotides having improved uptake and other properties |
| 02/24/2005 | US20050042755 Bacterium for use as vehicle for gene transport and transfer to preferential organs or tissues; tissue engineering and targeted somatic transgenesis |
| 02/24/2005 | US20050042754 Induction of the formation of insulin-producing cells via gene transfer of pancreatic beta-cell-associated transcriptional factor |
| 02/24/2005 | US20050042731 Four helical bundle cytokine family polypeptide for use in treatment, diagnosis and prevention of infection, cardiovascular, metabolic, developmental, skin, bone, inflammatory and autoimmune disorders |
| 02/24/2005 | US20050042729 Expression vector comprising nucleotide sequences conding immunoglobulin/interferon fusion for use in targeting and treatment of liver disorders |
| 02/24/2005 | US20050042671 Modulation of angiogenesis |
| 02/24/2005 | US20050042667 Expression vector comprising nucleotide sequences coding polypeptide for use in diagnosis, treatment and prevention of immune, hematopoietic, inflammatory and tumor diseases |
| 02/24/2005 | US20050042659 Secreted soluble alpha2delta-2, alpha2delta-3, or alpha2delta-4 calcium channel subunit polypeptides and screening assays using same |
| 02/24/2005 | US20050042647 Phosphorous-linked oligomeric compounds and their use in gene modulation |
| 02/24/2005 | US20050042646 RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
| 02/24/2005 | US20050042637 Pax-encoding vector and use thereof |
| 02/24/2005 | US20050042631 Cloning and characterization of two novel m-RNA transcription factors |
| 02/24/2005 | US20050042273 Covalently linking PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound to form a Complex; diagnostic and therapeutic agent; improving pharmacokinetic properties |
| 02/24/2005 | US20050042234 Method |
| 02/24/2005 | US20050042227 drug biological conjugates used in the diagnosis, prophylaxis, or treatment of nervous system disorders or lysosomal storage diseases; drug delivery; blood brain barriers |
| 02/24/2005 | US20050042206 Viral vectors having reduced virulence |
| 02/24/2005 | US20050042204 Method to protect transgenes from silencing |
| 02/24/2005 | US20050042203 Induction of antibodies against a hepatitis B surface antigen by sequential injection of bupivacaine and of a plasmid carrying a gene coding antigen; vaccine containing bare DNA is injected into host previously treated with substance capable of inducing coagulating necrosis of muscle fibers |
| 02/24/2005 | US20050042202 Gentamicin, amikacin, tobramycin, netilmicin, cephalosporin, ceftazidine, maxalactam, carbopenem, imipenem, aztreonam, ampicillin, penicillin, ureidopenicillin, augmentin, amphotericin, famvir and/or acyclovir; and Vpr protein, fragment or nucleic acid encoding; systemic inflammatory response syndrome |
| 02/24/2005 | DE20122302U1 Variante des Modifizierten Vaccinia-Ankara-Virus Modified version of the vaccinia Ankara virus |
| 02/24/2005 | CA2575926A1 Canine specific growth hormone releasing hormone |
| 02/24/2005 | CA2536146A1 Splice variants of erbb ligands, compositions and uses thereof |
| 02/24/2005 | CA2535683A1 Stem cell beacon |
| 02/24/2005 | CA2535680A1 Vigilant cells |
| 02/24/2005 | CA2535670A1 Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
| 02/24/2005 | CA2535007A1 Nogo receptor antagonists |
| 02/24/2005 | CA2532553A1 Methods for identifying compounds for regulating muscle mass or function using dopamine receptors |
| 02/23/2005 | EP1508620A1 Circular DNA molecule with conditional origin of replication, method for preparing same and use thereof in gene therapy |
| 02/23/2005 | EP1507873A1 Parallel stranded duplexes of deoxyribonucleic acid and methods of use |
| 02/23/2005 | EP1507866A2 Carotene synthase gene and uses therefor |
| 02/23/2005 | EP1507865A2 The frog prince, a transposon vector for gene transfer in vertebrates |
| 02/23/2005 | EP1507863A1 Plasmid stabilisation in vivo |
| 02/23/2005 | EP1507861A2 Vaccines |
| 02/23/2005 | EP1507856A1 Regulation of human serine/threonine kinase |
| 02/23/2005 | EP1507800A1 Use of monocarboxylate transporter protein for thyroid hormone transport |
| 02/23/2005 | EP1507795A1 Tumour-associated peptides that bond to mhc molecules |
| 02/23/2005 | EP1507791A2 Antisense antiviral agent and method for treating ssrna viral infection |
| 02/23/2005 | EP1507790A2 Human genes and gene expression products isolated from human prostate |
| 02/23/2005 | EP1507561A2 Compositions for delivering nucleic acids to cells |
| 02/23/2005 | EP1507560A1 Immune stimulating and controlling composition comprising bacterial chromosomal dna fragments and non-toxic lipopolysaccharides |
| 02/23/2005 | EP1507553A2 Pancreas-specific proteins |
| 02/23/2005 | EP1507551A2 The functional role and potential therapeutic use of pacap, vip and maxadilan in relation to adult neural stem or progenitor cells |
| 02/23/2005 | EP1507517A1 Microparticles bearing cells and active substances |
| 02/23/2005 | EP1035870B1 Compositions and methods for treatment of hepatitis c virus-associated diseases |
| 02/23/2005 | CN1584020A Differentiation of adipose stromal cells into osteobalsts and uses thereof |
| 02/23/2005 | CN1190491C PRV-gene and use thereof |
| 02/22/2005 | US6858722 Oligomer phosphoramidite compositions and processes for synthesizing the same |
| 02/22/2005 | US6858716 Drosophila recombination-associated protein and methods for use |
| 02/22/2005 | US6858586 Pituitary tumor transforming gene (PTTG) carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation |
| 02/22/2005 | US6858431 An osteoinductive soluble factor induced by the expression of human mineralization protein. |
| 02/22/2005 | US6858427 Sphingosine kinases |
| 02/22/2005 | US6858420 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 02/22/2005 | US6858418 Polypeptide for use in the treatment of cardiovascular and cell proliferation disorders |
| 02/22/2005 | US6858415 Comprises enzymatic polypeptide for treatment and diagnsis of muscular, aberrant glycolysis and/or immunological disorders |
| 02/22/2005 | US6858407 Nucleotide sequences coding polypetide for use in the treatment, prevention and diagnosis of gastrointestinal and apoptosis disorders |
| 02/22/2005 | US6858395 Diagnoss and treatment of muscular disorders; obtain tissue sample, detect preferential gene expression, amplified transcription of prferential gene indicates muscular disorder |
| 02/22/2005 | US6858390 Aptamers containing sequences of nucleic acid or nucleic acid analogues bound homologously, or in novel complexes |
| 02/22/2005 | US6858226 Fusogenic lipids and vesicles |
| 02/22/2005 | US6858225 A mixture of lipids containing a protonatable or deprotonatable lipid, such as polyoxyethylene glycol or polyamide oligomer modified lipid, or amino lipid is combined with a buffered aqueous solution of a charged drug |
| 02/22/2005 | US6858206 Methods for treating diseases caused by deficiencies of recombinant alpha-L-iduronidase |
| 02/22/2005 | US6858205 Administering genetic engineered polynucleotides having genetic deletion in glycoproteins of progenitor cells; gene therapy; drug delivery |
| 02/22/2005 | CA2185352C Novel muteins of ifn-.beta. |
| 02/17/2005 | WO2005014837A1 Novel active nucleic acid complexes for rna interference and the use thereof for inhibiting protein expression |